Darapladib: Additional Phase III data

Additional data from the double-blind, international Phase III STABILITY trial in 15,828 patients with chronic CHD showed that once-daily 160 mg oral darapladib plus standard of care (SOC) met the secondary endpoints of reducing the rates

Read the full 367 word article

How to gain access

Continue reading with a
two-week free trial.